M
Melissa Bourgeois
Researcher at Centers for Disease Control and Prevention
Publications - 10
Citations - 1426
Melissa Bourgeois is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Virus & Influenza A virus. The author has an hindex of 6, co-authored 10 publications receiving 1238 citations. Previous affiliations of Melissa Bourgeois include University of Florida.
Papers
More filters
Journal ArticleDOI
New world bats harbor diverse influenza A viruses.
Suxiang Tong,Xueyong Zhu,Yan Li,Mang Shi,Jing Zhang,Melissa Bourgeois,Hua Yang,Xianfeng Chen,Sergio Recuenco,Jorge Gomez,Li-Mei Chen,Adam Johnson,Ying Tao,C. Dreyfus,Wenli Yu,Ryan McBride,Paul J. Carney,Amy T. Gilbert,Jessie Chang,Zhu Guo,Charles T. Davis,James C. Paulson,James Stevens,Charles E. Rupprecht,Charles E. Rupprecht,Edward C. Holmes,Edward C. Holmes,Ian A. Wilson,Ruben O. Donis +28 more
TL;DR: Using consensus degenerate RT-PCR, a novel influenza A virus is identified in a flat-faced fruit bat from Peru, indicating that bats constitute a potentially important and likely ancient reservoir for a diverse pool of influenza viruses.
Journal ArticleDOI
A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus
Ying Wu,Myung-Sam Cho,David A. Shore,Manki Song,Jung-ah Choi,Tao Jiang,Yong-Qiang Deng,Melissa Bourgeois,Lynn M Almli,Hua Yang,Li-Mei Chen,Yi Shi,Jianxu Qi,An Li,Kye Sook Yi,MinSeok Chang,Jin Soo Bae,Hyunjoo Lee,Ji-Young Shin,James Stevens,SeoungSuh Hong,Cheng-Feng Qin,George F. Gao,Shin Jae Chang,Ruben O. Donis +24 more
TL;DR: The antibody, designated CT149, was isolated from convalescent patients infected with pandemic H1N1 in 2009 and is found to neutralize all tested group 2 and some group 1 influenza A viruses by inhibiting low pH-induced, HA-mediated membrane fusion.
Journal ArticleDOI
Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model.
K. K. Seino,Maureen T. Long,E. P. J. Gibbs,R. A. Bowen,Sarah E. Beachboard,P. P. Humphrey,M. Dixon,Melissa Bourgeois +7 more
TL;DR: A severe challenge model that produces clinical West Nile virus (WNV) disease was used to test the efficacy of three commercially available equine WNV vaccines in horses and resulted in 100% survivorship (protection from the onset of WNV encephalitis and viremia).
Journal ArticleDOI
Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.
M. Jaber Hossain,M. Jaber Hossain,Melissa Bourgeois,Fu-Shi Quan,Aleksandr S. Lipatov,Jae-Min Song,Jae-Min Song,Li-Mei Chen,Richard W. Compans,Ian A. York,Sang-Moo Kang,Sang-Moo Kang,Ruben O. Donis +12 more
TL;DR: Testing the immunogenicity and protective efficacy of a VLP vaccine containing hemagglutinin (HA) and M1 from the 2009 pandemic H1N1 influenza virus in ferrets shows that i.n. vaccination with VLPs has the potential for highly efficacious vaccination against influenza.
Journal ArticleDOI
Gene expression analysis in the thalamus and cerebrum of horses experimentally infected with West Nile virus.
TL;DR: Investigation of both innate and adaptive components of immunity was seen, with higher levels of expression correlating with survival, and increased expression of suppressor of cytokine signaling 3 in horses exposed to WNV which functions to suppress innate immunity.